THURSDAY, SEPTEMBER 18TH
METHODOLOGICAL ISSUES
CHAIRMEN : L. SCHNEIDER (LOS ANGELES), H. FELDMAN (VANCOUVER)
ORAL COMMUNICATIONS
08:00
05 CRITICAL EVALUATION OF SELF-RATED QUALITY OF LIFE IN AD
H.J. Gertz, M. Berwig, H. Leicht
Memory Clinic, Department of Psychiatry, University Clinic, Leipzig
08:15
06 BRIDGING FROM CLINICAL ENDPOINTS TO ESTIMATES OF TREATMENT VALUE FOR EXTERNAL DECISION MAKERS
Carolyn
W. Zhu, PhD (1,2); Christopher Leibman, PharmD, MS (3); Ray Townsend,
PharmD (3); Trent McLaughlin, PhD (3); Nikolaos Scarmeas, MD, MSc
(4,5); Marilyn Albert, PhD (6); Jason Brandt, PhD (6); Deborah Blacker,
MD, ScD (7); Mary Sano, PhD (1,8); and Yaakov Stern, PhD (4,5).
This work is from the Geriatric Research, Education, and Clinical
Center (GRECC) and Program of Research on Serious Physical and Mental
Illness, Targeted Research Enhancement Program (TREP), James J. Peters
VA Medical Center, Bronx NY USA (1); Brookdale Department of
Geriatrics, Mount Sinai School of Medicine, New York, NY USA (2); Elan
Pharmaceuticals, Inc., South San Francisco, CA USA (3); Cognitive
Neuroscience Division of the Taub Institute for Research in Alzheimer’s
Disease and the Aging Brain (4); Gertrude H. Sergievsky Center and the
Department of Neurology, Columbia University Medical Center, New York,
NY USA (5); Department of Psychiatry and Behavioral Sciences, Johns
Hopkins University, Baltimore, MD USA (6); Department of Psychiatry,
Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
(7); and Department of Psychiatry, Mount Sinai School of Medicine, New
York, NY USA (8).
08:30
07 INVOLVING
PATIENTS WITH ALZHEIMER’S DISEASE IN CLINICAL TRIALS : A COMPARATIVES
STUDY OF ETHICS COMMITTEES FROM FRANCE AND QUEBEC
G Bravo (1), MF Dubois (1), S Hansel (2), AM Duguet (3)
(1) Sherbrooke University Institute of Geriatrics, Sherbrooke, Canada;
(2) Conférence Nationale des CPP, Paris, France; (3) INSERM Unité 558,
Université Paul Sabatier, Toulouse, France
08:45
08 NON-PHARMACOLOGICAL TRIALS FOR BPSD IN NURSING HOME PATIENTS WITH ALZHEIMER'S DISEASE
P.H. Robert (1), E.Reynish (2), C Cantet (3), B.Vellas (2),
(1) Centre Mémoire de Ressources et de Recherche, CHU de Nice – Inserm
JE 2441 - UNSA; (2) Inserm, U558, F-31073, Toulouse, France -
University Toulouse III, Toulouse, F-31073, France ; Department of
Internal Medicine and Clinical Gerontology, Toulouse University
Hospital, F-31059, France; (3) Department of Epidemiology and Public
Health, Toulouse University Hospital Toulouse, F-31073, France.
LECTURES
09:00
L4 Interest of NTB as cognitive outcome for therapeutic trials
Michael GRUNDMANN (San Diego)
9:30
L5 Clinical design and outcome for symptomatic trials
Lutz FROELICH (Mannheim)
10:00 – 10:45
Coffee break and Poster Session
10:45
L6 The Measurement of Cognitive Change in Clinical Trials: Theory, Methodological Problems and Solutions
Paul MARUFF (Melbourne)
11:15
L7 The Measurement of Cognitive Change in Clinical Trials: Encouraging CaCase Studies with a New statistical Approach
Peter SNYDER (Providence)
11.45
L8 Selection of efficacy outcomes in disease-modifying trials that are meaningful to clinicians, patients and payers
Serge GAUTHIER (Montréal)
12:15
L9 Use of new criteria for clinical trial
Bruno DUBOIS (Paris)
12:45 – 14:30
Lunch Time
CHAIRMEN : L. FROELICH (MANNHEIM), PH. ROBERT (NICE)
14:30
L10 The experience for Clinical Trial in vascular dementia
Jean-Marc ORGOGOZO (Bordeaux)
15:00
L11 Clinical trial for behavioural disorders in dementia
Lon SCHNEIDER (Los Angeles)
15:30
L12 New area for Alzheimer Clinical Trials
Zaven S. KHACHATURIAN (Las Vegas)
16:00 – 16:30
Coffee break and Poster Session
UPDATE ON CLINICAL TRIALS
CHAIRMEN : JM. ORGOGOZO (BORDEAUX) – M. GRUNDMANN (SAN DIEGO)
16:30
SYNAPSE FORMATION IS ENHANCED BY ORAL ADMINISTRATION OF URIDINE AND DHA, THE CIRCULATING PRECURSORS OF BRAIN PHOSPHATIDES
R.J. Wurtman , Massachusetts Institute of Technology, Cambridge, MA, USA 02139
16:50
BUTYRYLCHOLINESTERASE AND DISEASE PROGRESSION IN MILD COGNITIVE IMPAIRMENT AND EARLY ALZHEIMER’S DISEASE
Howard Feldman, University of British Columbia Hospital, Vancouver, British Columbia, Canada
17:10
CHALLENGES
IN THE CONDUCT OF DISEASE-MODIFYING TRIALS IN AD: PRATICAL EXPERIENCE
FROM A PHASE 2 TRIAL OF TAU AGGREGATION INHIBITOR THERAPY
Claude Wischik, University of Abeerdeen, Aberdeen (UK)